Expertise in
9
conditions

Dr. Seth Baum

Internal Medicine
Office
7900 Glades Rd Ste 400, 
Boca Raton, FL 
Expertise in
9
conditions
Office
7900 Glades Rd Ste 400, 
Boca Raton, FL 

Overview

Seth Baum is an Internal Medicine provider practicing medicine in Boca Raton, Florida.

Dr. Baum is highly rated in 9 conditions, according to our data. His clinical expertise encompasses High Cholesterol, Defective Apolipoprotein B-100, Homozygous Familial Hypercholesterolemia (HoFH), and Heterozygous Familial Hypercholesterolemia (HeFH).

He is actively involved in clinical research, co-authoring 106 peer reviewed articles and participating in 20 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Office
7900 Glades Rd Ste 400, Boca Raton, FL 33434

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

LOWER: Lomitapide Observational Worldwide Evaluation Registry
LOWER: Lomitapide Observational Worldwide Evaluation Registry
Enrollment Status: Completed
Publish Date: May 12, 2026
Intervention Type: Drug
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Drug
Study Drug: TQJ230
Study Phase: Phase 3
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Mixed Dyslipidemia
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Mixed Dyslipidemia
Enrollment Status: Completed
Publish Date: April 14, 2026
Intervention Type: Drug
Study Phase: Phase 2
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
Enrollment Status: Completed
Publish Date: March 24, 2026
Intervention Type: Drug
Study Drug: ARO-APOC3
Study Phase: Phase 2
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Homozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol (ORION-13)
Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Homozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol (ORION-13)
Enrollment Status: Completed
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drug: Inclisiran
Study Phase: Phase 3
Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Heterozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol (ORION-16)
Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Heterozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol (ORION-16)
Enrollment Status: Completed
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drug: Inclisiran
Study Phase: Phase 3
A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2025
Intervention Type: Drug
Study Phase: Phase 4
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: August 24, 2025
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)
Enrollment Status: Completed
Publish Date: August 20, 2025
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
View 9 Less Clinical Trials

106 Total Publications

Correction: Rates of acute pancreatitis and cardiovascular events among adults with severe or extreme hypertriglyceridemia in US clinical practice.
Correction: Rates of acute pancreatitis and cardiovascular events among adults with severe or extreme hypertriglyceridemia in US clinical practice.
Journal: Lipids in health and disease
Published: March 03, 2026
Similar Doctors
Expertise in
27
conditions
Dr. Barry Davis
Internal Medicine
Expertise in
27
conditions
Dr. Barry Davis
Internal Medicine

Office

1601 Clint Moore Rd Ste 100, 
Boca Raton, FL 
 (6.0 miles away)
561-939-0200
Languages Spoken:
English
See accepted insurances

Barry Davis is an Internal Medicine provider practicing medicine in Boca Raton, Florida. Dr. Davis is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Bronchiectasis, Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), and Pneumonia.

Expertise in
62
conditions
Dr. James Chong
Internal Medicine
Expertise in
62
conditions
Dr. James Chong
Internal Medicine

Office

4675 Linton Blvd Ste 202, 
Delray Beach, FL 
 (7.2 miles away)
561-495-5700
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Chong is an Internal Medicine provider practicing medicine in Delray Beach, Florida. Dr. Chong is highly rated in 62 conditions, according to our data. His clinical expertise encompasses Angiodysplasia of the Colon, Barrett Esophagus, Gastroesophageal Reflux Disease (GERD), Endoscopy, and Gastrectomy.

Expertise in
50
conditions
Dr. David Levenson
Internal Medicine
Expertise in
50
conditions
Dr. David Levenson
Internal Medicine

Office

7301 W Palmetto Park Rd Ste 108B, 
Boca Raton, FL 
 (1.5 miles away)
561-391-4441
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Levenson is an Internal Medicine provider practicing medicine in Boca Raton, Florida. Dr. Levenson is highly rated in 50 conditions, according to our data. His clinical expertise encompasses Maturity Onset Diabetes of the Young, Type 2 Diabetes (T2D), Hyperparathyroidism, and Hypercalcemia.

Frequently Asked Questions about Dr. Seth Baum

How do I make an appointment with Dr. Seth Baum?

You can book an appointment with Dr. Seth Baum by calling their office at 561-488-5535. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Seth Baum a top-rated expert for High Cholesterol?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Seth Baum is classified as an Elite expert for High Cholesterol, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Seth Baum specialize in?

While Dr. Seth Baum is a Internal Medicine, they have specific expertise in High Cholesterol, Defective Apolipoprotein B-100, and Homozygous Familial Hypercholesterolemia (HoFH). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Seth Baum participate in research or clinical trials?

Yes. Dr. Seth Baum has published 106 articles and abstracts on conditions like High Cholesterol. You can view a list of Dr. Seth Baum's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Seth Baum accept my insurance?

Dr. Seth Baum accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 561-488-5535 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Baum's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile